Skip to main content
SynAct Pharma logo

SynAct Pharma — Investor Relations & Filings

Ticker · SYNACT ISIN · SE0008241491 LEI · 549300RRYIEFEQ72N546 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2026-02-18 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SYNACT

About SynAct Pharma

https://synactpharma.com/en/

SynAct Pharma is a clinical-stage biotechnology company developing innovative medicines designed to resolve inflammation rather than solely inhibit it. The company's approach focuses on resolution therapy by leveraging melanocortin biology to restore immune balance. Its lead candidate, Resomelagon (AP1189), is a once-daily oral therapy that selectively activates melanocortin receptors on key immune cells. SynAct Pharma's development programs target a broad range of inflammatory conditions, including early intervention in chronic diseases to limit progression and the modulation of hyperinflammatory stages in acute viral diseases to reduce the risk of severe organ dysfunction.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for SynAct Pharma AB, covering the fourth quarter and full year 2025. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analyses, and management commentary. It is not an announcement of a report (RPA) as it contains the full financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. Q4 2025
2026-02-18 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the fourth quarter and annual results 2025' and contains comprehensive financial statements, including income statements, balance sheets, cash flow reports, and management commentary for the period ending December 2025. It is clearly a periodic financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report. Q4 2025
2026-02-18 English
Återköp av aktier i Synact Pharma AB
Transaction in Own Shares Classification · 100% confidence The document is a press release from SynAct Pharma AB detailing the repurchase of its own shares (share buyback) over a specific period. It includes a table of transaction dates, volumes, and prices, and explicitly references the company's share buyback program. According to the filing definitions, 'Transaction in Own Shares' (POS) is the correct category for reports of a company buying back its own shares.
2026-02-17 Swedish
Repurchase of shares in Synact Pharma AB
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement regarding the company's repurchase of its own shares (share buyback program). It details the volume, price, and dates of the transactions conducted on Nasdaq Stockholm. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2026-02-17 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a change in major shareholding (flaggningsmeddelande). It details a transaction where Avanza Bank Holding AB's subsidiary, Försäkringsaktiebolaget Avanza Pension, sold shares in SynAct Pharma AB, crossing the 10% threshold. This fits the definition of a Major Shareholding Notification (MRQ).
2026-01-28 Swedish
SynAct Pharmas utser Malin Wikstrand till tillförordnad CFO
Board/Management Information Classification · 100% confidence The document is a press release announcing the appointment of a new interim Chief Financial Officer (CFO) at SynAct Pharma AB. This falls directly under the category of management changes, which is defined as 'Announcement of changes in the company's board of directors or senior management'.
2026-01-19 Swedish

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.